At a glance
- Originator Genelabs Technologies
- Class Antifungals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Candidiasis
Most Recent Events
- 18 Nov 2004 This compound is still in active development
- 29 Jul 2002 Preclinical trials in Candidiasis in USA (unspecified route)